{
    "clinical_study": {
        "@rank": "21842", 
        "arm_group": [
            {
                "arm_group_label": "Escalation", 
                "arm_group_type": "Experimental", 
                "description": "MEDI4736 will be combined with gefitinib to assess safety and tolerability"
            }, 
            {
                "arm_group_label": "Expansion Arm", 
                "arm_group_type": "Experimental", 
                "description": "MEDI4736 will be combined with gefitinib"
            }
        ], 
        "brief_summary": {
            "textblock": "This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability,\n      pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with\n      MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung cancer (NSCLC). The study\n      consists of two phases: Escalation phase and an expansion phase to be conducted in locally\n      advanced or metastatic NSCLC subjects"
        }, 
        "brief_title": "MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Non-Small Cell Lung Cancer(NSCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "In Escalation phase: MEDI4736 and gefitinib in NSCLC subjects In Expansion phase: Subjects\n      with EGFR mutation positive locally advanced or metastatic NSCLC will be enrolled in\n      expansion arms. Initiation of expansion arms with the recommended dose of MEDI4736 in\n      combination with gefitinib will be based on an adequate safety and tolerability profile of\n      the combination from the escalation phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Provision of signed and dated, written informed consent\n\n          2. Male or female aged 18 years and older.\n\n          3. Subjects must have a. In the escalation phase, locally advanced or metastatic NSCLC\n             subjects who have either failed to respond or relapsed following any line of standard\n             treatment, were unable to tolerate, or were not eligible for standard treatment\n\n          4. a.For Escalation Phase: At least one lesion (measurable and/or non-measurable) b. For\n             Expansion Phase: At least one measurable lesion.\n\n          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n        Key Exclusion Criteria:\n\n          1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer\n             treatment.\n\n          2. Any investigational agent, chemotherapy, immunotherapy, biologic, hormonal within 28\n             days of the first dose of study treatment\n\n          3. Inadequate bone marrow reserve or organ function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088112", 
            "org_study_id": "D791PC00001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Escalation", 
                    "Expansion Arm"
                ], 
                "description": "Gefitinib QD", 
                "intervention_name": "Gefitinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Escalation", 
                    "Expansion Arm"
                ], 
                "intervention_name": "MEDI4736", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gefitinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "NSCLC", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Dr B Creelan"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "FL 33612"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr D Gibbons"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "TX 77030"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr L Q Chow"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "WA98109"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)", 
        "other_outcome": {
            "description": "These samples will be used for exploratory biomarker studies.", 
            "measure": "Biomarkers will be analyzed", 
            "safety_issue": "No", 
            "time_frame": "From screening to 30 days of last dose of study treatment, assessed up to 30 months"
        }, 
        "overall_contact": {
            "email": "ClinicalTrialEnquiries@Medimmune.com", 
            "last_name": "Joyson J Karakunnel, MD, MSc, FACP", 
            "phone": "301-398-1610"
        }, 
        "overall_contact_backup": {
            "email": "jianmei.lin@astrazeneca.com", 
            "last_name": "Jianmei Jianmei Lin", 
            "phone": "0086 21 60302721"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Korea: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "AEs: Type, incidence, severity, seriousness and relationship to study medications of adverse events (AE) (graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE]; Safety Labs: Blood and urine samples for determination of clinical chemistry, hematology, coagulation, thyroid function tests and urinalysis will be taken at the visits; any laboratory abnormalities, and including dose-limiting toxicities (DLTs), ECG measurements and Creatinine Clearance", 
            "measure": "Escalation Phase: safety and tolerability: AEs, laboratory data, vital signs, ECG changes and Echo. Expansion Phase: safety and tolerability of the recommended dose for MEDI4736; AEs, laboratory data, vital signs, ECG changes and Echo.", 
            "safety_issue": "Yes", 
            "time_frame": "From first dose of study treatment until 90 days after the last dose, assessed up to 32 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088112"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "At each visit subjects will be programmatically assigned a RECIST visit response of CR, PR, SD or PD depending on the status of their disease compared to baseline and previous assessments; Objective response rate: the percentage of subjects who have at least one visit response of CR or PR prior to any evidence of progression . Disease control rate: the percentage of subjects who have at least one visit response of CR or PR or SD prior to any evidence of progression. Progression Free Survival (PFS) : the time from start of study treatment to the first documentation of objective disease progression (PD) or death from any cause.", 
                "measure": "To obtain a preliminary assessment of the anti-tumour activity of gefitinib in combination with MEDI4736 by evaluation of tumour response", 
                "safety_issue": "No", 
                "time_frame": "From baseline assessment to disease progression, assessed up to 30 months"
            }, 
            {
                "description": "Assessed by evaluating the number and percentage of subjects who develop detectable anti-drug antibodies (ADAs). The impact of ADAs on overall MEDI4736 PK will also be evaluated.", 
                "measure": "To determine the immunogenicity of MEDI4736 in combination with gefitinib: anti-drug antibodies (ADAs)", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study treatment until 90 days after the last dose, assessed up to 32 months"
            }, 
            {
                "description": "Individual MEDI4736 concentrations will be tabulated by dose cohort along with descriptive statistics. Noncompartmental PK data analysis will be performed", 
                "measure": "To determine the pharmacokinetics of MEDI4736", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study treatment until 90 days after the last dose, assessed up to 32 months"
            }, 
            {
                "description": "PD-L1 levels before and after treatment with MEDI4736 will be measured to evaluate its association with response to treatment with MEDI4736 and clinical outcome", 
                "measure": "To assess MEDI4736 pharmacodynamics in subjects receiving MEDI4736 in combination with gefitinib.", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study treatment until 90 days after the last dose, assessed up to 32 months"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}